All posts by imreal

Associated Hearing Professionals Celebrates March 3, World Hearing Day


“Noise-induced hearing loss is a preventable and significant factor,” said Dr. Margaret Fritsch Juelich, audiologist.

In 2007, the World Health Organization designated March 3 as World Hearing Health Day in order to raise awareness of the growing numbers of those suffering from hearing loss and the importance of hearing health care.

Associated Hearing Professionals and The American Academy of Audiology are focused on educating the public about hearing loss and the impact it has on quality of life. We are grateful that this awareness day was created to shine a light on the significance of hearing loss.

“Noise-induced hearing loss is a preventable and significant factor,” said Dr. Margaret Fritsch Juelich, audiologist. Associated Hearing Professionals and a member of the American Academy of Audiology. “This growing health problem is often unrecognized in U.S. adults, adolescents and children and it leads to a long list of problems including depression, isolation, academic delays, impaired communication and cognitive decline. In 2013, a study from the Johns Hopkins Center of Aging and Health concluded that those with untreated hearing loss showed a faster decline in cognition (brain function) than normal hearing individuals. Untreated hearing loss can also cause an increase in cognitive load, and this can lead to anxiety.

The many consequences of untreated hearing loss lead to social isolation and that contributes to depression and a decrease in brain stimulation. Treating hearing loss allows people to become more engaged socially and social engagement is considered one of the most important factors affecting quality of life.

While age is still the greatest factor in hearing loss, many younger people also experience hearing problems due to exposure to loud music and noises including occupational noise. Among adults aged 70 and older with hearing loss who could benefit from hearing aids, fewer than one in three (30 percent) has ever used them. With adults aged 20 to 69 only approximately 16 percent of those who would benefit from hearing aids have ever used them.

“Audiologists diagnose and treat hearing loss,” Dr. Juelich explained. “Anyone suspecting a hearing issue should see an audiologist who will perform a series of tests to determine the problem, if there is one, and will then recommend treatment.”

Some signs of hearing loss may include:

  • Having to turn up the volume of the television, radio, or stereo and having other family members complain that the volume is too loud.
  • Difficulty understanding people speaking to you and asking people to repeat themselves.
  • Difficulty with phone conversations and understanding the other person.
  • Sudden inability to hear the door bell, the dog barking, and other household sounds.
  • People telling you that you speak too loudly.
  • Ringing in the ears.

School-aged children with hearing loss will sometimes exhibit poor school performance because they can’t understand the teacher assignments or classroom interactions. If hearing loss has been present from a young age, they often don’t recognize the loss and can’t identify the problem.

The audiologists of Associated Hearing Professionals are passionate about improving quality of life through better hearing. A mild hearing loss is not a mild problem. Untreated hearing loss has a significant impact on overall health and interactions with family, friends and co-workers. Improve your hearing, improve your health and improve your happiness!

The American Academy of Audiology is the world’s largest professional organization of, by and for audiologists. The active membership of more than 12,000 is dedicated to providing quality hearing care services through professional development, education, research, and increased public awareness of hearing and balance disorders. To find an audiologist, go to http://www.audiology.org/FindAnAudiologist.

Share article on social media or email:

Uptrust Announces Over $1.3M In Funding For Engineering, Partnerships Teams


Since its founding in 2017, Uptrust has secured partnerships with more than 50 new jurisdictions and now works with 40 percent of the 15 most populated counties in the United States, and reducing FTA (Failure to Appear) rates by 50 percent in certain jurisdictions.

Uptrust, the San Francisco-based technology company fighting mass incarceration, announced today that it has completed a $1.3 million fundraising round.

“We’re excited to have such a strong collection of financial supporters that also perceive the untapped opportunity to build tools to impact lives but at the expense of communities impacted by mass incarceration,” said Jacob Sills, co-founder of Uptrust.

Uptrust, the San Francisco-based technology company fighting mass incarceration, announced today that it has completed a $1.3 million fundraising round. Since its founding in 2017, Uptrust has secured partnerships with more than 50 new jurisdictions and now works with 40 percent of the 15 most populated counties in the United States, and reducing FTA (Failure to Appear) rates by 50 percent in certain jurisdictions. The financing round — comprised of a combination of grants and investment — allows Uptrust to broaden both its engineering and sales capabilities, and to service the growing number of government customers seeking and pursuing assistance in reducing jail populations. The investment will also improve the Uptrust best-in-class product, which ensures people attend mandatory appointments in the criminal justice system by reminding them of their obligations and connecting them to relevant social services.

“The odds should not be stacked against millions of Americans who get involved with the justice system. Uptrust is making a course correction through technology in the most obvious way: enabling communication and support through mobile devices that we all use and rely on every day,” said Jordan Blashek, Director at Schmidt Futures, a philanthropic initiative founded by Eric and Wendy Schmidt. “We are pleased to support Uptrust as it expands upon its mission to keep people out of jail that shouldn’t be there.”

Millions of Americans have gone to jail because of a missed court date or probation check-in, which may result in a revocation of previously imposed bail conditions or a new criminal charge in certain jurisdictions. The downstream effects of these small mistakes are huge: many judges and prosecutors fail to release individuals after subsequent interactions with law enforcement when not confident that a person will show up for all of their future court dates, or judges set an unaffordable bail amount, also resulting in jail. Incarcerating these individuals results in a staggering amount of government waste. As a result, local governments spend more than $9 billion on unnecessary pretrial incarceration, and an additional $1 billion issuing and enforcing FTAs.

Created in 2016, Uptrust’s product initially focused on improving communication between public defenders and clients through text messages. The level of need for Uptrust’s software has proven to be larger than initially expected. Through more than 50 state and county government partnerships across the Country plus the U.S. Territory of Guam, Uptrust has reduced FTAs by 50 percent in many of its jurisdictions, saving millions of dollars of taxpayer funds, and ultimately keeping productive citizen lives in tact. The new funding will help expand that number to support more than 150 jurisdictions and one million defendants by the end of 2020.

“Uptrust is building a differentiated and sustainable business by creating value for all stakeholders in the system, and we’re excited to invest in its continued growth,” said Tony Davis, an investor in Uptrust and founder of Inherent Group, a leading ESG investor. “Municipal customers save money that can be redirected toward other needs. Criminal justice and law enforcement professionals gain back the hours spent dealing with the fallout of FTAs. And most importantly, low income individuals navigating the justice system receive a tool that helps them meet their commitments — while avoiding the burden of fees that most for-profit enterprises have historically charged them.”

Uptrust’s goal is to eliminate all technical violations in the criminal justice system without expanding the use of surveillance and supervision. Providing an easy-to-use, modern mobile experience for the tens of millions of low-income Americans who have interacted with our country’s legal system goes a far way in achieving this goal. Part of this new funding will improve Uptrust’s product, including the launching of the new Uptrust mobile app for public defender clients. Clients will be able to message multiple stakeholders (such as their attorney and social worker) and learn about local opportunities such as free or reduced transportation to court and expungement clinics.

“Community organizers and advocates have done an incredible job at educating the broader public and key stakeholders about the problems associated with pretrial detention and money bail. We at Uptrust are trying to do a small part by building technology products that enhance those efforts and allow local jurisdictions to decarcerate without expanding the use of supervision or electronic monitoring,” said Jacob Sills, co-founder and CEO of Uptrust. “We’re excited to have such a strong collection of financial supporters that also perceive the untapped opportunity to build tools to impact lives but at the expense of communities impacted by mass incarceration.”

ABOUT UPTRUST

Uptrust is a communication and engagement tool helping the indigent accused arrive at court for their scheduled hearings and other mandatory appointments. By improving relationships within the criminal justice system, Uptrust has proven to keep low-income individuals charged with crimes out of jail on bench warrants and technical violations, while also saving attorneys time and reducing the cost to the municipality, county or state. Uptrust currently is contracted with more than 50 jurisdictions and public defender offices around the US, and intends to increase the number to over 100 in early 2020. The platform reaches over 500,000 individuals. With offices in San Francisco, CA and Northampton, MA, Uptrust is a public benefit corporation supported by the Draper Richards Kaplan Foundation, RFK Human Rights, Schmidt Futures, Inherent Foundation and the Heising-Simons Foundation. To learn more about Uptrust, visit http://www.Uptrust.co.

Share article on social media or email:

Valerie Rose’s newly released “Dear God, I Hate You Yet You Love Me Anyway” brings a wellspring of hope, healing, and faith by sharing insights and personal experiences


News Image

“Dear God, I Hate You Yet You Love Me Anyway: Finding Faith through the World’s Filth”: a powerful testimony of God’s love that shines right through a heart that has been filled with anger, loneliness, hopelessness, and hurt. “Dear God, I Hate You Yet You Love Me Anyway: Finding Faith through the World’s Filth” is the creation of published author Valerie Rose, a college professor who teaches business, management, ethics, critical thinking, and college success. She enjoys volunteering with American Cancer Society, Susan G. Komen, FFA Agricultural Education, and serving in various ministries at Harvest Church.

An excerpt from the book further explains, “Valerie Rose is an ordinary, middle-aged, middle-class, working woman whose willingness to share her own oppositional view on faith, religion, the world’s filth, and building a relationship with God in the midst of it all is real, raw, inspiring, and encourages others to do the same. She is a daughter, sister, cousin, aunt, wife, mother, stepmother, nana, and friend whose passion is to inspire others to turn their frowns upside down and embrace God’s love through all life’s trials and tribulations.

“Using her own personal struggles in building a relationship with God, Valerie shows how recognizing God’s love for her in the midst of anger, agony, awkwardness, abandonment, alcoholism, and abuse helped her to replace hatred with healing. She overcame abuse and abandonment, fears, hurts, and other hang-ups to go on teaching and encouraging others to learn and grow.

“Valerie offers life-transforming insights not only about how to overcome hatred, hurts, hang-ups, and painful circumstances many identify with, but also how to heal, grow, and embrace God’s love from those experiences and then help others to do the same. Her personal stories will inspire you to see your own hatred, hurts, and hang-ups that have built barriers around your heart and will help you to begin seeking healing, grace, and love; to recognize God loves all of you and He is there for you.”

Published by Christian Faith Publishing, Valerie Rose’s new book is a thought-provoking read that will help readers to identify themselves within these pages and reflect on their own life journey just as the author writes of her own story of finding faith through the filth.

View a synopsis of “Dear God, I Hate You Yet You Love Me Anyway: Finding Faith through the World’s Filth” on YouTube.

Consumers can purchase“Dear God, I Hate You Yet You Love Me Anyway: Finding Faith through the World’s Filth” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Dear God, I Hate You Yet You Love Me Anyway: Finding Faith through the World’s Filth,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Clinerion and iClusion partner to boost the identification and recruitment of more patients into clinical trials.


Together, the partners’ joint mission is to increase patient participation in studies to its full potential by optimizing protocol design, enabling study sites to efficiently start up their trials locally and plan and meet realistic patient recruitment and therefore total timeline targets.

This new clinical trial optimization partnership also facilitates a total study site network activation for all trials, beyond the study sites already chosen to participate, by facilitating online referral and activation services.

iClusion makes clinical research accessible for physicians and their patients by connecting sponsors and their research protocols with research sites. Connecting all stakeholders and automating standardized local approval procedures in one networked platform accelerates total study timelines and makes innovative products available to more patients faster.

Clinerion makes real-world patient data accessible for analysis so that study protocols can be optimized with real patients in mind and real-world patient data can drive study feasibility and patient recruitment.

Both iClusion and Clinerion maintain cloud platforms which bring together participants from across the clinical study ecosystem, comprising sponsors, hospitals and clinicians, and treating physicians and patients. However, the partners offer complementary support and solutions throughout the product development process.

“Never in history has the R&D engine in pharmaceuticals been more productive, driving a pool of promising new agents,” says Edwin Klumper, CEO of iClusion. “The growing pipeline of targeted and personalized medicines puts tremendous pressure on more trials to be conducted in smaller, more well-defined patient populations. As a result, patient recruitment has become the bottleneck, nowadays, which is delaying progress and withholding many patients from the benefits of participation. I am pleased that Clinerion and iClusion are partnering to start tackling the identification and recruitment of the right patients into the right studies to bolster trial conduct and innovation.”

“Our collaboration re-emphasizes that patients are at the heart of clinical development and clinical trial conduct,” says Ian Rentsch, CEO of Clinerion. “Our combined services cover trials operations from protocol design through operational feasibility, site selection, local approvals, startup of study sites and patient recruitment. This partnership is therefore ideally positioned to optimize and advance protocols faster, reach more study sites and offer more patients the possibility to participate in research.”

Clinerion and iClusion will present their combined offerings at the upcoming SCRS’s European Site Solution Summit in Lisbon, Portugal, on March 9-10, 2020. Clinerion will be at Booth #25.

European Site Solution Summit website: http://www.eusitesolutionssummit.com.

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: http://www.clinerion.com

Clinerion’s Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:

Le Vin Chin

Director, Head of Marketing & Communications

Clinerion Ltd

Elisabethenanlage 11, 4051 Basel, Switzerland

Tel.: +41 61 865 60 54

media@clinerion.com

About iClusion

Clinical trials don’t just advance science; they also serve as in-the-moment treatment alternatives for patients. iClusion aims to make the clinical trial process faster, more effective, and more accessible for cancer patients and oncologists. The Trial Eye platform of iClusion connects study sponsors, hospitals, physicians, and their patients in a closed-loop ecosystem, non-existing today. Rather than each group remaining siloed, iClusion’s clinical study infrastucture invites various stakeholders to connect and interact speeding up clinical trial processes and patient recruitment and therefore the entire drug development process. iClusion believes its new model is nothing short of revolutionary. It’s the only initiative designed from the viewpoint of the 2 most important stakeholders within clinical trials; the patient and their treating physician. If they have easy access to clinical trials and can participate, drug development can speed up. The Social Impact and Goal is that each cancer patient should be offered the opportunity to participate in an experimental treatment whereas today only 5% of patients do get this opportunity to a last life line.

iClusion website: http://www.iclusion.com

For more information, please contact:

Hanneke Janssen

iClusion

General Manager

iClusion BV

Groot Handelsgebouw, Stationsplein 45 (Unit A4.004), 3013 AK, Rotterdam, The Netherlands

Tel.: 0031 6 20684080

hanneke.janssen@iclusion.com

Share article on social media or email:

Blackbird Technologies and M2M Solutions Settle IoT Patent Case


This patent describes an important improvement to the ever-expanding world of IoT technology. We are very pleased that the inventor of this cutting edge technology continues to see the value of her important contribution.

Blackbird Technologies has settled a patent infringement lawsuit related to programmable wireless communications devices.

In August 2014, M2M Solutions, LLC initiated a patent infringement action against Telit Wireless Solutions Inc. (“Telit”) in the U.S. District Court for the District of Delaware (14-cv-1103). The patent at issue is U.S. Patent No. 8,648,717 (“the ‘717 patent”), entitled “Programmable Communicator.” The ‘717 patent relates to an innovative machine-to-machine module that controls communication between two or more machines. These machine-to-machine communications encompass a variety of applications in which one machine is able to remotely monitor a second machine in a relatively autonomous fashion. In June 2017, Blackbird Technologies acquired the ‘717 patent and was joined as a plaintiff to the action. The parties settled the case in January 2020.

Wendy Verlander, President and CEO of Blackbird Technologies, said, “This patent describes an important improvement to the ever-expanding world of IoT technology. It is prevalent in fields such as automated meter reading, asset tracking and fleet management, industrial automation and controls, and the remote control of certain consumer devices and appliances. We are very pleased that the inventor of this cutting edge technology continues to see the value of her important contribution.”

About Blackbird Technologies

Blackbird Technologies provides a unique opportunity for individual inventors and small companies to realize the value of their patents. By using in-house expertise, rather than expensive law firms, Blackbird Technologies is able to litigate at reduced costs and achieve results that equal or exceed what a law firm would recover. This company creates efficiencies that make it possible for individual inventors and small companies to see the end game – realizing the true value of their patents.

Share article on social media or email:

Sebela Pharmaceuticals Announces FDA Approval of Pizensy™ for oral solution for the Treatment of Chronic Idiopathic Constipation in Adults


News Image

The approval of Pizensy represents a major step forward in treatment options for CIC. Pizensy will be the only FDA approved product which the patient can self-titrate based on their own results for stool consistency, said Jack A. Di Palma, M.D.

Sebela Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Pizensy™ (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC) in adults. Pizensy is a simple monosaccharide sugar alcohol that exerts an osmotic effect, causing the influx of water into the small intestine leading to a laxative effect.

“The approval of Pizensy represents a major step forward in treatment options for CIC. Pizensy will be the only FDA approved product which the patient can self-titrate based on their own results for stool consistency,” said Jack A. Di Palma, M.D., Professor of Medicine and Fellowship Program Director of the Division of Gastroenterology at the University of South Alabama College of Medicine and Past-President of the American College of Gastroenterology. “Pizensy will allow practitioners and patients to jointly take control of their condition using a product with the same proven and safe mechanism of action as we have seen in bowel prep products such as SUPREP® Bowel Prep Kit.”

Unlike current prescription treatments which are solid oral doses, Pizensy is mixed with the patient’s fluid of choice, e.g., water, juice, coffee, tea or soda, and taken once a day at whatever time the patient prefers, preferably with food. Pizensy allows patients to adjust the dose of the product. In the clinical trials versus placebo, approximately 25% of patients were able to at least temporarily reduce their dose.

Pizensy is expected to be available in the U.S. in the second half of 2020. Pizensy is a New Chemical Entity and is expected to have patent protection until 2037. Sebela intends to commercialize Pizensy in the U.S. with a marketing partner and has received preliminary expressions of interest from a number of interested parties.

CIC is a complex, functional GI disorder defined by symptoms including fewer than three bowel movements a week and hard-to-pass or incomplete bowel movements, for which there is no identifiable cause.1,2 CIC affects approximately 33 million Americans and an estimated 14 percent of the global population.2 Almost 4.7M brand prescriptions were written for products indicated for CIC in 2019, representing gross sales of $2.36B and growth rates of +6% and +16% versus 2018 respectively.3

The efficacy and safety of Pizensy were evaluated in three Phase 3 clinical trials which included more than 1,400 patients. These included a 6-month, double-blind, placebo-controlled study, a 12-week, blinded head to head study versus lubiprostone (AMITIZA®) and a 12-month, open-label, chronic use study.

Over the first 12-week course of treatment, patients treated with Pizensy achieved a significantly greater efficacy response compared to placebo (26% vs. 13%, p less than 0.001). This response was sustained in the Pizensy group during Weeks 13 to 24. In both pivotal trials, efficacy responders were defined as patients who had at least three complete spontaneous bowel movements (CSBMs) in a given week and an increase of at least one CSBM over baseline in the same week for at least nine out of 12 weeks, including at least three of the last four weeks.

Over course of treatment, patients who received Pizensy had statistically significant improvements as compared to placebo in stool frequency (as measured by the number of spontaneous and complete spontaneous bowel movements per week) and stool consistency (as measured by the Bristol Stool Form Scale).

The most common adverse event reported in the clinical trials versus placebo was Upper Respiratory Tract Infection at a rate of 9% compared to 6% of patients treated with placebo. Other adverse events reported at a lower frequency include flatulence and diarrhea. The rates of diarrhea and severe diarrhea were similar between the Pizensy and placebo groups. Overall discontinuation rates were low among patients treated with Pizensy at 4% as compared to placebo at 3%.

Indications and Usage

Pizensy is indicated for chronic idiopathic constipation in adults.

IMPORTANT SAFETY INFORMATION

Pizensy™ is contraindicated in patients known or suspected mechanical gastrointestinal obstruction or galactosemia.

The most common adverse reactions observed when taking Pizensy (greater than 3%)%) are upper respiratory tract infection, flatulence, diarrhea, Increased blood creatinine phosphokinase, abdominal distension and high blood pressure.

The following adverse reactions have been identified during post-approval use of lactitol outside the United States, hypersensitivity reactions, including rash and pruritus.

Pizensy may reduce the absorption of concomitantly administered oral medications. Administer oral medications at least 2 hours before or 2 hours after Pizensy.

Please click here for Full Prescribing Information

About Chronic Idiopathic Constipation (CIC)

CIC affects approximately 14 percent of the global population, disproportionately affecting women and older adults.2 People with CIC have persistent symptoms of difficult and infrequent bowel movements.1 In addition to physical symptoms including abdominal bloating and discomfort, CIC can adversely affect an individual’s quality of life, including increasing stress levels and anxiety.1

About Pizensy™

Pizensy™ (lactitol) for oral solution is a once-daily product wherein 20 grams of the product is mixed with 4 to 8 ounces of fluid, e.g., water, juice or soda for the treatment of chronic idiopathic constipation in adults. If the patient experiences loose stools the dose of Pizensy™ can be lowered to 10 grams mixed with 4 to 8 ounces of fluid.

About Sebela Pharmaceuticals

Sebela is a private, US-focused growth-oriented specialty pharmaceutical company developing and commercializing gastroenterology, women’s health and dermatology prescription products. The company is a pioneer in gastroenterology therapy for bowel cleansing prior to colonoscopy having developed multiple innovative prescription bowel prep and constipation products such as GoLYTELY®, NuLYTELY®, MiraLAX® and SUPREP® Bowel Prep Kit. Sebela has numerous further advances in bowel prep therapy in late-stage clinical development including one NDA currently under review by the FDA. Sebela also has two next-generation Intra-Uterine Devices (IUDs) for contraception in development which holds the promise of better patient experience in addition to excellent efficacy.

Sebela has offices in Roswell, GA; Braintree, MA; and Dublin Ireland, has annual net sales of approximately $250 million and has grown to over 300 employees through strategic acquisitions and organic growth. Sebela’s products in Gastroenterology and Dermatology maintain number one market share positions in the marketplace as branded prescription products for their indications.3

Please visit sebelapharma.com for more information.

Forward-Looking Statement

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of Pizensy; growth and opportunity, including peak sales and the potential demand for Pizensy, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash used for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Sebela does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

1Thomas R, Luthin D. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Pharmacotherapy Pub. 2015; 613-630.

2 Suares NC, Ford AC. Prevalence of, and risk factors for chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(9): 1582-1591.

3IQVIA. National Prescription Audit Report. December 2019.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.

MiraLAX is a registered trademark of Bayer Healthcare LLC

SOURCE: Sebela Pharmaceuticals

Sebela Pharmaceuticals

Jai Wall

VP, Corporate Affairs

jai.wall@sebelapharma.com

Scarlett Hotel Group Adds Historic Chicago Art Deco Hotel to Portfolio


Travelodge Hotel Downtown Chicago by Wyndham

“Growing up in Chicago, as the first generation in my family to be born and raised here, I am extremely humbled to now be managing such a historic property in the city I call home,” said Zio Pekovic, principal and co-founder of Scarlett Hotel Group.

Scarlett Hotel Group (SHG) announced today that the company has taken over management of the Travelodge Hotel Downtown Chicago by Wyndham. Formerly known as the Harrison Hotel, the historic building located at 65 East Harrison at the corner of Harrison and Wabash, just steps from Grant Park and Columbia College, is a major win for the entrepreneurial hospitality management and development group.     

“Growing up in Chicago, as the first generation in my family to be born and raised here, I am extremely humbled to now be managing such a historic property in the city I call home,” said Zio Pekovic, principal and co-founder of SHG. “It’s truly an amazing opportunity to take a property that’s an important part of the city’s past and make it shine again.”

The Travelodge Hotel Downtown Chicago by Wyndham was originally named the Harrison Hotel when it was completed in 1930. The 12-story structure was designed by architect Alfred S. Alschuler, who also designed the London Guarantee Building (now the London House hotel) and the Chicago Mercantile Exchange. Upon its original grand opening, advertisements boasted “circulating ice water,” access to a radio for only 25 cents, and the first attached hotel garage in the city.

Today, the 233-guest room building provides visitors with easy access to all that Chicago has to offer, including Michigan Avenue, Millennium Park, Soldier Field, and the museum campus. SHG’s immediate plans for the Travelodge Downtown include a hotel-wide refresh to bring the property up to the standards of today’s modern traveler.

About the Travelodge Hotel Downtown Chicago by Wyndham

Located at 65 East Harrison Street in downtown Chicago, the Travelodge Hotel Downtown Chicago by Wyndham is now under the management of Scarlett Hotel Group. The historic, 233-room art deco hotel is located adjacent to Chicago’s Grant Park, Buckingham Fountain and Lake Michigan, and is an ideal loca-tion for guests looking to visit Chicago’s most popular attractions, including Chicago museums, Michigan Avenue, Soldier Field, McCormick Place, and Millennium Park. Amenities include free Wi-Fi, a variety of rooms including family/oversized rooms and rooms with kitchenettes, and two onsite restaurants. Visit https://www.wyndhamhotels.com/travelodge/chicago-illinois/travelodge-hotel-downtown-chicago/ or call 1-312-574-3335 for reservations.

About Scarlett Hotel Group

With offices in Chicago and Nashville, Scarlett Hotel Group (SHG) was founded by hotel industry leaders Andrew Scarlett, Rob Sadoff and Zio Pekovic. The company is a people-focused organization with a passion for hotel development, acquisitions, management and sales using core values to improve traditional industry standards. Visit http://scarletthotelgroup.com/.

# # #

Media Contact: Beth Strautz, beth@vaguspr.com, 773-895-5387

Share article on social media or email:

MediaPlatform® Customers Cite Crucial Role of Webcasting for Business Continuity


Markets are reacting to fears that the coronavirus outbreak will negatively impact the ability of companies to conduct their day-to-day operations. Fortunately, our customers have contingency communications and meeting plans in place and business broadcasts play a central role in those plans.

Amidst global fears of a widening coronavirus outbreak, webcasting is playing a central role in keeping international businesses connected and productive.

Video-savvy enterprises can quickly convert in-person meetings, events and activities into virtual venues that use live video for interactive, real-time information sharing and collaboration. In this way, online video – such as that provided by MediaPlatform’s Enterprise Video Platform – brings employees, partners and customers together to ensure that travel restrictions have a minimal impact on business operations.

“Markets are reacting to fears that the coronavirus outbreak will negatively impact the ability of companies to conduct their day-to-day operations. Fortunately, our customers have contingency communications and meeting plans in place and business broadcasts play a central role in those plans,” said Mike Newman, CEO of MediaPlatform.

MediaPlatform’s Enterprise Video Platform includes it next-generation live webcasting platform, MediaPlatform® Broadcaster, which gives producers easy-to-use, browser-based multimedia production capabilities with enterprise-class security and reliability, and the MediaPlatform® Event Success Dashboard (ESD), a real-time analytics tool that lets business broadcasters monitor in real time how audiences are reacting to webcast content via an audience sentiment widget that lets viewers register sentiment votes using intuitive emoticons.

Its end-to-end enterprise video platform also includes the MediaPlatform® On Demand video content management portal, and MediaPlatform’s video delivery capabilities – including its Smartpath network overlay rules engine for management of failover and redundancy across multiple vendor technologies and the MediaPlatform® Edge eCDN.

About MediaPlatform

MediaPlatform is a leading enterprise video platform enabling large-scale live streaming and on-demand video that companies use to engage remote employees, empower and motivate workers by giving them the power to rapidly self-educate and share knowledge, and attract and keep top talent. MediaPlatform gives customers an end-to-end solution and world-class services so they can use their networks for business broadcasts, consolidate disconnected video systems, accelerate their digital workplace transition, and gain insights into the reach and impact of their video communications.

Share article on social media or email:

Teresa M. Caringi’s newly released “Shepherd’s Daughter” is a compelling handbook that inspires the readers to keep their focus to Jesus as they journey their lives


News Image

“Shepherd’s Daughter”: a contemporary handbook that guides the readers in following the path that God has prepared for them. “Shepherd’s Daughter” is the creation of published author Teresa M. Caringi, a writer who has served God in various churches and on prayer and healing teams. She is an author sharing God’s teachings and inspirational stories inspired and led by the Holy Spirit.

Caringi writes, “Faith contains the power to birth the supernatural. It raises you above all circumstances to believe in what is not yet seen. The path walked is paved by faith. Maybe you’re at a place where you’ve been knocked down by storm after storm, and you’re struggling to get back up. Situations you believed God to change have worsened. This hour your weakness shall know God’s strength. What appears as your defeat and end births forth victory and a new beginning. Circumstances appeared as defeat and the end for Jesus as he climbed the hill to Calvary. In reality, it was his greatest victory and a new beginning for all. Without death, there’d be no resurrection. The same is true in our walk. Peter walked on water until his focus changed from Jesus to circumstance. Yet remember that Jesus lifted him before he sank. As he shall do for you.”

“All is not as it appears. You only need to regain focus on whom your faith rests. May the obstacles overcome, lessons learned, and inspirational teachings throughout my shared journey grant birth within you to the revelation of faith to believe in what is not yet seen and the strength to perseverance beyond circumstance unto victory.”

Published by Christian Faith Publishing, Teresa M. Caringi’s new book shares a wonderful reading experience as the author gives readers a gleaming light that will guide them throughout their journey in life as a son or daughter of the good shepherd.

With this book, Caringi brings the readers back to a scenario where Jesus lifted up Peter, so they may be able to realize that God will never abandon His people and is willing to redirect them.

View a synopsis of “Shepherd’s Daughter” on YouTube.

Consumers can purchase “Shepherd’s Daughter” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Shepherd’s Daughter,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

NucleusHealth™ presenting at HIMSS in collaboration with Microsoft Azure


News Image

“Companies like NucleusHealth are critical in helping healthcare organizations use technology to address industry challenges and seize opportunities to impact people’s lives in a positive way.”

NucleusHealth, a medical image management technology company and teleradiology services provider, announced their appearance inside the Microsoft Azure for Healthcare booth at the 2020 Healthcare Information Management Systems Society (HIMSS) Global Health Conference and Exhibition. The company will showcase its Nucleus.io platform that is disrupting the imaging space with its cloud native PACS solution.

NucleusHealth chose Microsoft Azure to power the Nucleus.io medical image management platform because of its dependable security and longstanding presence in the healthcare industry. “NucleusHealth delivers its Nucleus.io platform via Microsoft Azure to nearly 7,000 image management organizations. Using a cloud-based platform also enables our teleradiologists to access and read 1.3 million studies per year,” says Claude Hooton, NucleusHealth President and Chief Operating Officer. “We live and breathe the solution that we provide to clients. Azure is a proven cloud provider that allows us to enhance our own cloud platform in day-to-day operations.”

“We’re pleased NucleusHealth is joining us at HIMSS to showcase how technology is helping healthcare organizations succeed in transforming patient care and their businesses. Microsoft Azure helps unify people, devices, apps and information responsibly by prioritizing compliance, security and trust,” said Gareth Hall, director of business strategy for Worldwide Healthcare at Microsoft Corp. “Companies like NucleusHealth are critical in helping healthcare organizations use technology to address industry challenges and seize opportunities to impact people’s lives in a positive way.”

NucleusHealth will be demonstrating the flexibility of its image management platform and how organizations can utilize the Nucleus.io platform to enhance workflows, elevate user experience, reduce IT burden, and eventually replace aging enterprise imaging systems altogether. Claude Hooton, NucleusHealth President and COO will also be presenting in a Lunch and Learn session to show how Nucleus.io cooperates in the market by enabling artificial intelligence and machine learning applications for imaging needs through the usage of standards.

The Nucleus.io cloud-based image management platform is comprised of modular solutions. They are all completely in a web browser and provide image exchange, remote reading, downtime PACS, cloud PACS, and a platform-as-a-service for enabling medical software applications. Nucleus.io is one of the first imaging solutions to use client-side rendering paired with proprietary adaptive streaming protocols to bypass any latency issues currently experienced with all other cloud solutions. This approach allows for the viewing of large medical images in a browser with the same performance as on-premise workstations. More information will be available throughout HIMSS 2020 in Orlando at the Microsoft Azure exhibit, booth No. 2300, Orange County Convention Center.

About NucleusHealth

NucleusHealth is advancing patient care through innovation in cloud-based medical image management, facilitating a global image exchange accessible by patients, physicians and healthcare networks. NucleusHealth licenses its Nucleus.io software as a service (SaaS) and web-scale platform as a service (PaaS) technologies to healthcare organizations and companies across the globe. The company’s StatRad teleradiology service was founded in 1996, by radiologists for radiologists, and develops and implements forward-thinking solutions for radiology groups. For more information, call us at +1(858)251-3400, visit us at http://www.nucleushealth.io, or connect with us on Twitter or LinkedIn.

Share article on social media or email: